Fast Market Research announces the availability of the new Current Partnering report, "Global Immunology Partnering 2010-2016: Deal trends, players and financials", on their comprehensive research portal
Boston, MA -- (SBWIRE) -- 04/22/2016 -- The Global Immunology Partnering 2010-2016: Deal trends, players and financials report provides comprehensive understanding and unprecedented access to the immunology/autoimmune partnering deals and agreements entered into by the worlds leading healthcare companies
Global Immunology Partnering 2010 to 2016 provides the full collection of Immunology disease deals signed between the world's pharmaceutical and biotechnology companies since 2010.
Trends in Immunology partnering deals
Financial deal terms for headline, upfront and royalty by stage of development
Immunology partnering agreement structure
Immunology partnering contract documents
Top Immunology deals by value
Most active Immunology dealmakers
Get More Details on this Report and a Full Table of Contents at Global Immunology Partnering 2010-2016: Deal trends, players and financials
Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor's product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.
The report takes readers through the comprehensive Immunology disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Immunology deals.
The report presents financial deal terms values for Immunology deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.
The initial chapters of this report provide an orientation of Immunology dealmaking trends.
Chapter 1 provides an introduction to the report.
Chapter 2 provides an overview of the trends in Immunology dealmaking since 2010 covering trends by year, deal type, stage of development, technology type and therapeutic indication.
Chapter 3 includes an analysis of financial deal terms covering headline value, upfront payment, milestone payments and royalty rates.
Chapter 4 provides a review of the leading Immunology deals since 2010. Deals are listed by headline value. The chapter includes the top 25 most active Immunology dealmakers, together with a full listing of deals to which they are a party. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.
Chapter 5 provides comprehensive access to Immunology deals since 2010 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.
Chapter 6 provides a comprehensive directory of all Immunology partnering deals by specific Immunology target announced since 2010. The chapter is organized by specific Immunology therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
In addition, a comprehensive appendix is provided with each report of all Immunology partnering deals signed and announced since 2010. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
The report also includes numerous tables and figures that illustrate the trends and activities in Immunology partnering and dealmaking since 2010.
In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Immunology technologies and products.
Global Immunology Partnering 2010 to 2016 is intended to provide the reader with an in-depth understanding and access to Immunology trends and structure of deals entered into by leading companies worldwide.
Global Immunology Partnering 2010 to 2016 includes:
Trends in Immunology dealmaking in the biopharma industry since 2010
Analysis of Immunology deal structure
Access to headline, upfront, milestone and royalty data
Access to hundreds of Immunology deal contract documents
Comprehensive access to over 3500 Immunology deal records
The leading Immunology deals by value since 2010
Most active Immunology dealmakers since 2010
In Global Immunology Partnering 2010 to 2016, available deals and contracts are listed by:
Upfront payment value
Royalty rate value
Stage of development at signing
Deal component type
About Fast Market Research
Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.
Browse all Pharmaceuticals research reports at Fast Market Research
You may also be interested in these related reports:
-Global Vaccine Partnering Terms and Agreements 2010-2016: Deal trends, players and financials
-Global Oncology Partnering 2010-2016: Deal trends, players and financials
-Global Regenerative Medicine Partnering 2010-2016: Deal trends, players, financials and forecasts
-Global Cardiovascular Partnering 2010-2016: Deal trends, players and financials
-Global Gynecology Partnering 2010-2016: Deal trends, players and financials